Objective B cells are likely to contribute to the pathogenesis of systemic lupus
erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III …

Objective A number of open‐label studies have suggested the potential benefit of rituximab
(RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled …

Objective Safer and more effective therapies are needed for the treatment of systemic lupus
erythematosus (SLE). B lymphocytes have been shown to play fundamental pathogenic …

Objective Rituximab appears to be effective in many studies of systemic lupus
erythematosus (SLE), with variable initial clinical response and time to relapse. However …

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre
Registry Page 1 Clinical and Experimental Rheumatology 2015; 33: 449-456. Efficacy and …

The wide spectrum of clinical manifestations and high relapse rate represent a therapeutic
challenge in systemic lupus erythematosus (SLE). Observational studies suggested efficacy …

Although corticosteroids and immunosuppressants are widely used for the treatments of
systemic lupus erythematosus (SLE), safer and more effective therapies are prerequisite. We …

Objective The objective of this article is to evaluate the safety and clinical outcome of
rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of …

Objective Conventional treatment of systemic lupus erythematosus (SLE) and lupus
nephritis (LN) is associated with damage accrual, hence increased morbidity rate. Off-label …

Objective To describe the clinical outcome and safety of rituximab (RTX) treatment in
systemic lupus erythematosus (SLE) patients with severe manifestations or whose disease …